Suppr超能文献

异基因造血干细胞移植中胸腔积液的发病率、病因及转归

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.

作者信息

Modi Dipenkumar, Jang Hyejeong, Kim Seongho, Deol Abhinav, Ayash Lois, Bhutani Divaya, Lum Lawrence G, Ratanatharathorn Voravit, Manasa Richard, Mellert Kendra, Uberti Joseph P

机构信息

Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, Michigan.

Department of Oncology, Biostatistics Core, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.

出版信息

Am J Hematol. 2016 Sep;91(9):E341-7. doi: 10.1002/ajh.24435. Epub 2016 Jul 14.

Abstract

Pleural effusion is a known entity in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT); however, the incidence, risk factors, and morbidity-mortality outcomes associated with pleural effusions remain unknown. We retrospectively evaluated pleural effusions in 618 consecutive adult patients who underwent allogeneic HSCT from January 2008 to December 2013 at our institution. Seventy one patients developed pleural effusion at a median of 40 days (range, 1 - 869) post-HSCT with the cumulative incidence of 9.9% (95% CI, 7.7 - 12.5%) at 1 year. Infectious etiology was commonly associated with pleural effusions followed by volume overload and serositis type chronic GVHD. In multivariate analysis, higher comorbidity index (P = 0.03) and active GVHD (P = 0.018) were found to be significant independent predictors for pleural effusion development. Higher comorbidity index, very high disease risk index, ≤7/8 HLA matching, and unrelated donor were associated with inferior overall survival (OS) (P < 0.03). More importantly, patients with pleural effusion were noted to have poor OS in comparison to patients without pleural effusion (P < 0.001). Overall, pleural effusion is a frequently occurring complication after allogeneic HSCT, adding to morbidity and mortality and hence, early identification is required. Am. J. Hematol. 91:E341-E347, 2016. © 2016 Wiley Periodicals, Inc.

摘要

胸腔积液在接受异基因造血干细胞移植(HSCT)的患者中是一种已知情况;然而,与胸腔积液相关的发病率、风险因素以及发病-死亡结局仍不清楚。我们回顾性评估了2008年1月至2013年12月在我们机构接受异基因HSCT的618例连续成年患者的胸腔积液情况。71例患者在HSCT后中位40天(范围1 - 869天)出现胸腔积液,1年时累积发病率为9.9%(95%CI,7.7 - 12.5%)。感染病因通常与胸腔积液相关,其次是容量超负荷和血清病型慢性移植物抗宿主病(GVHD)。在多变量分析中,较高的合并症指数(P = 0.03)和活动性GVHD(P = 0.018)被发现是胸腔积液发生的显著独立预测因素。较高的合并症指数、非常高的疾病风险指数、≤7/8 HLA匹配以及无关供者与较差的总生存期(OS)相关(P < 0.03)。更重要的是,与无胸腔积液的患者相比,有胸腔积液的患者OS较差(P < 0.001)。总体而言,胸腔积液是异基因HSCT后常见的并发症,增加了发病率和死亡率,因此需要早期识别。《美国血液学杂志》91:E341 - E347,2016年。© 2016威利期刊公司

相似文献

引用本文的文献

8
Pleural Fluid Analysis in Neutropenia.中性粒细胞减少症患者的胸腔积液分析
Ann Am Thorac Soc. 2022 Nov;19(11):1946-1948. doi: 10.1513/AnnalsATS.202204-331RL.

本文引用的文献

1
Chronic GvHD-associated serositis and pericarditis.慢性移植物抗宿主病相关浆膜炎和心包炎。
Bone Marrow Transplant. 2015 Aug;50(8):1098-104. doi: 10.1038/bmt.2015.105. Epub 2015 May 11.
7
Large pericardial effusion as a complication in adults undergoing SCT.成人 SCT 后并发大量心包积液。
Bone Marrow Transplant. 2011 Oct;46(10):1353-6. doi: 10.1038/bmt.2010.297. Epub 2010 Nov 29.
8
Defining the intensity of conditioning regimens: working definitions.定义预处理强度:工作定义。
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. doi: 10.1016/j.bbmt.2009.07.004. Epub 2009 Sep 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验